AbbVie Files New Infringement Case Over Blockbuster Drug Humira
AbbVie Inc. filed a patent infringement lawsuit Wednesday against German rival Boehringer Ingelheim Pharmaceuticals Inc., the second case in Delaware that seeks to block sales of a less-expensive biosimilar version of Humira, AbbVie's top-selling drug.
This premium content is reserved for Delaware Law Weekly subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now